Platelet-activating factor acetylhydrolase in plasma lipoproteins from patients with ischemic stroke
- PMID: 1636183
- DOI: 10.1161/01.str.23.8.1090
Platelet-activating factor acetylhydrolase in plasma lipoproteins from patients with ischemic stroke
Abstract
Background and purpose: Platelet-activating factor is a potent bioactive phospholipid and may play an important role in occlusive vascular diseases. To assess the inactivation of this autacoid in plasma, we measured platelet-activating factor acetylhydrolase activity in plasma low density and high density lipoproteins from patients with ischemic stroke.
Methods: Low density and high density lipoproteins were separated by ultracentrifugation from plasma of 33 patients with cerebral thrombosis and 31 age-matched healthy control subjects, and platelet-activating factor acetylhydrolase activity in each fraction was assayed.
Results: The average values of platelet-activating factor acetylhydrolase activity in low density lipoprotein from patients and control subjects were 41 +/- 18 and 29 +/- 17 nmol/ml per minute, respectively, and the difference was statistically significant (p less than 0.01 U test). There was no difference in activity in high density lipoprotein between the two groups (16 +/- 11 versus 14 +/- 9 nmol/ml per minute, respectively).
Conclusions: The increased plasma platelet-activating factor acetylhydrolase activity in stroke patients is primarily attributable to the increased binding to low density lipoprotein, and this increase may be an adaptation to the augmented generation of platelet-activating factor in ischemic stroke.
Similar articles
-
Human plasma platelet-activating factor acetylhydrolase. Association with lipoprotein particles and role in the degradation of platelet-activating factor.J Biol Chem. 1987 Mar 25;262(9):4215-22. J Biol Chem. 1987. PMID: 3549727
-
Lipoproteins alter the catalytic behavior of the platelet-activating factor acetylhydrolase in human plasma.Proc Natl Acad Sci U S A. 1989 Apr;86(7):2393-7. doi: 10.1073/pnas.86.7.2393. Proc Natl Acad Sci U S A. 1989. PMID: 2928339 Free PMC article.
-
Variation in plasma platelet-activating factor degradation and serum lipids after acute myocardial infarction.Coron Artery Dis. 1993 Feb;4(2):187-93. doi: 10.1097/00019501-199302000-00009. Coron Artery Dis. 1993. PMID: 8269210
-
Platelet-activating factor acetylhydrolase: is it good or bad for you?Curr Opin Lipidol. 2004 Jun;15(3):337-41. doi: 10.1097/00041433-200406000-00015. Curr Opin Lipidol. 2004. PMID: 15166791 Review.
-
Clinical aspects of plasma platelet-activating factor-acetylhydrolase.Biochim Biophys Acta. 2006 Nov;1761(11):1359-72. doi: 10.1016/j.bbalip.2006.06.017. Epub 2006 Sep 1. Biochim Biophys Acta. 2006. PMID: 17049457 Review.
Cited by
-
Metabolic processing of PAF.Clin Rev Allergy. 1994 Winter;12(4):309-27. doi: 10.1007/BF02802298. Clin Rev Allergy. 1994. PMID: 7743460 Review. No abstract available.
-
Inflammatory mediators of cerebral endothelium: a role in ischemic brain inflammation.Brain Pathol. 2000 Jan;10(1):113-26. doi: 10.1111/j.1750-3639.2000.tb00248.x. Brain Pathol. 2000. PMID: 10668901 Free PMC article. Review.
-
Neuroprotection during cardiac surgery: a randomised trial of a platelet activating factor antagonist.Heart. 2003 Aug;89(8):897-900. doi: 10.1136/heart.89.8.897. Heart. 2003. PMID: 12860868 Free PMC article. Clinical Trial.
-
New Insights Into the Pathologic Roles of the Platelet-Activating Factor System.Front Endocrinol (Lausanne). 2021 Mar 15;12:624132. doi: 10.3389/fendo.2021.624132. eCollection 2021. Front Endocrinol (Lausanne). 2021. PMID: 33796070 Free PMC article. Review.
-
Pharmacogenetic meta-analysis of baseline risk factors, pharmacodynamic, efficacy and tolerability endpoints from two large global cardiovascular outcomes trials for darapladib.PLoS One. 2017 Jul 28;12(7):e0182115. doi: 10.1371/journal.pone.0182115. eCollection 2017. PLoS One. 2017. PMID: 28753643 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources